Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Public offering nets $200mm for PTC Therapeutics

Executive Summary

PTC Therapeutics Inc. netted $200mm through a public offering of 6.7mm common shares at $30.20. Proceeds are earmarked for continued work on the company's gene therapy and alternative splicing programs for rare diseases and cancer; gene therapy manufacturing activities; and commercialization of Translarna (ataluren) outside of the US for nonsense mutation Duchenne muscular dystrophy (nmDMD), Emflaza (deflazacort) in the US for DMD, and Tegsedi (inotersen) and Waylivra (volanenorsen) for rare diseases in Latin America and the Caribbean.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies